Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
10 papers
Recent·Most cited
C. S. Delaveris, S. Kong, J. Glasgow, R. P. Loudermilk, L. L. Kirkemo, F. Zhao, F. Salangsang, P. Phojanakong, J. A. C. Serrano, V. Steri, J. A. Wells
The paper uses chemoproteomics to identify immunogenic cell surface substrates of CK2α in the tumor microenvironment, showing that extracellular phosphorylation can generate immunogenic antigens.
bioRxiv · Mar 20, 2024Biochemistry
B. Gini, P. Gui, W. Wu, D. L. Kerr, L. Tan, D. Barbosa, V. Olivas, P. Allegakoen, C. Gomez, P. Halliday, S. Elmes, V. Steri, T. Chakrabarti, T. G. Bivona, C. M. Blakely
This study shows that CDK4/6 upregulation causes DNA replication stress and genomic instability, leading to resistance to EGFR inhibitors in lung cancer, and suggests combining CDK4/6 and EGFR inhibitors as a treatment.
bioRxiv · Mar 12, 2024 · PreprintCancer Biology
C. Kasap, A. Izgutdina, B. Patino-Escobar, A. Kang, N. Chilakapati, N. Akagi, H. Johnson, T. Rashid, J. Werner, A. Barpanda, H. Geng, Y.-H. T. Lin, S. Rampersaud, D. Gil-Alos, A. Sobh, , A. Wiita
Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.
bioRxiv · Feb 24, 2024Cancer Biology
B. Popescu, C. Stahlhut, T. C. Tarver, S. Wishner, B. J. Lee, C. A. C. Peretz, C. Luck, P. Phojanakong, J. A. Camara Serrano, H. Hongo, J. M. Rivera, S. Xirenayi, J. A. Chukinas, V. Steri, S. K. Tasian, , C. C. Smith
This study shows that combining SHP2 and BCL2 inhibition synergistically kills FLT3- and KIT-mutant AML cells and xenografts.
bioRxiv · Dec 1, 2022 · PreprintCancer Biology
K. Mandal, G. Wicaksono, C. Yu, J. J. Adams, M. R. Hoopmann, W. C. Temple, B. P. Escobar, M. Gorelik, C. H. Ihling, M. A. Nix, A. Naik, E. Ramos, C. Kasap, V. Steri, J. A. C. Serrano, , A. P. Wiita
The paper identifies an AML-specific conformation of Integrin-β2 using structural surfaceomics and demonstrates its targeting by CAR-T cells.
bioRxiv · Oct 10, 2022 · PreprintCancer Biology
P. Choudhry, C. Kasap, B. Patino Escobar, O. Gugliemini, H. Geng, V. Sarin, A. Kang, A. Kishishita, S. Rampersaud, L. Sarah, Y.-H. T. Lin, N. Paranjape, P. Ramkumar, M. Marcoulis, D. Wang, , A. Wiita
This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.
bioRxiv · Aug 4, 2021 · PreprintCancer Biology
S. A. Lim, J. Zhou, A. J. Martinko, Y.-H. Wang, E. V. Filippova, V. Steri, D. Wang, S. G. Remesh, J. Liu, B. Hann, A. A. Kossiakoff, M. J. Evans, K. K. Leung, J. A. Wells
The paper develops antibodies targeting proteolytic neo-epitopes of CDCP1 in RAS-driven cancers, showing improved tumor specificity and safety.
bioRxiv · Jun 14, 2021 · PreprintBiochemistry
I. D. Ferguson, Y.-H. T. Lin, C. Lam, H. Shao, M. Hale, K. M. Tharp, M. C. Mariano, V. Steri, D. Wang, P. Phojanokong, S. T. Tuomivaara, B. Hann, C. Driessen, B. V. Ness, J. E. Gestwicki, A. P. Wiita
This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.
bioRxiv · Apr 21, 2020Cancer Biology
L. E. Sanman, I. W. Chen, J. M. Bieber, V. Steri, B. Hann, L. F. Wu, S. J. Altschuler
The paper identifies that modulating transit-amplifying cell proliferation alters intestinal epithelial cell-type composition through lineage-based mechanisms.
bioRxiv · Mar 12, 2020Cell Biology
S. K. Elledge, H. L. Tran, A. H. Christian, V. Steri, B. Hann, F. D. Toste, C. J. Chang, J. A. Wells
This study systematically identifies engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation, finding stable sulfimide modifications comparable to cysteine-maleimide conjugation.
bioRxiv · Aug 28, 2019Bioengineering